Biomerica, Inc. (BMRA)
Stock Price:
$8.81 USD
-0.06 (-0.68%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $8.84 +0.03 (0.34%) Aug 7, 7:52 PM
Key Info
| Market Cap |
103.54M |
| Revenue (ttm) |
5.13M |
| Net Income (ttm) |
-2.64M |
| Shares Out |
11.75M |
| EPS (ttm) |
-0.27 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$8.81 |
| Previous Close |
$8.87 |
| Change ($) |
-0.06 |
| Change (%) |
-0.68% |
| Day's Open |
8.87 |
| Day's Range |
8.63 - 9.03 |
| Day's Volume |
257,386 |
| 52-Week Range |
2.05 - 23.39 |
More Stats
| Market Cap |
103.54M |
| Enterprise Value |
102.77M |
| Earnings Date (est) |
Aug 27, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
11.75M |
| Float |
9.26M |
| EPS (basic) |
-0.27 |
| EPS (diluted) |
-0.27 |
| FCF / Share |
-0.19 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
491,793 |
| Short Ratio |
0.56 |
| Short % of Float |
6.39% |
| Beta |
-0.71 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
20.17 |
| PB Ratio |
22.62 |
| Revenue |
5.13M |
| Operating Income |
-2.68M |
| Net Income |
-2.64M |
| Free Cash Flow |
-1.85M |
| Net Cash |
767,374 |
| Net Cash / Share |
0.07 |
| Gross Margin |
25.17% |
| Operating Margin |
-52.19% |
| Profit Margin |
-51.40% |
| FCF Margin |
-35.94% |
| ROA |
-25.22% |
| ROE |
-61.09% |
| ROIC |
-55.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$10.25*
(16.35% upside)
Low
9.50
Current: $8.81
High
11.00
Target: 10.25
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | 5.20 | 5.56 | 5.79 | 5.14 | 4.96 | 5.12 | 6.47 | 6.08 |
| Revenue Growth | -6.53% | -3.93% | 12.68% | 3.58% | -3.09% | -20.89% | 6.44% | - |
| Gross Profit | 1.29 | 1.75 | 2.02 | 1.52 | 1.54 | 1.67 | 2.43 | 2.30 |
| Operating Income | -2.41 | -1.48 | -0.95 | -0.83 | -0.67 | -0.45 | 0.51 | 0.50 |
| Net Income | -2.39 | -1.47 | -0.91 | -1.50 | -0.33 | -0.22 | 0.54 | 0.55 |
| Shares Outstanding | 9.21 | 8.57 | 8.33 | 7.63 | 7.55 | 7.37 | 7.02 | 6.89 |
| Earnings Per Share | -0.26 | -0.17 | -0.11 | -0.20 | -0.04 | -0.03 | 0.07 | 0.08 |
| EPS Growth | - | - | - | - | - | - | -12.5% | - |
| Operating Cash Flow | -2.24 | -1.17 | -0.72 | -0.21 | -0.41 | -0.86 | 1.39 | 0.15 |
| Capital Expenditures | -0.10 | -0.13 | -0.10 | -0.09 | -0.01 | -0.14 | -0.26 | -0.16 |
| Free Cash Flow | -2.35 | -1.30 | -0.82 | -0.30 | -0.41 | -1.00 | 1.14 | -0.02 |
| Cash & Equivalents | 0.69 | 1.20 | 1.23 | 1.89 | 1.09 | 1.51 | 2.47 | 1.08 |
| Total Debt | - | - | - | - | - | - | - | 0.04 |
| Net Cash / Debt | 0.69 | 1.20 | 1.23 | 1.89 | 1.09 | 1.51 | 2.47 | 1.03 |
| Assets | 5.25 | 5.22 | 5.02 | 5.73 | 6.12 | 6.47 | 6.39 | 5.57 |
| Liabilities | 1.26 | 0.90 | 0.53 | 0.51 | 0.52 | 0.56 | 0.56 | 0.59 |
| Book Value | 3.98 | 4.33 | 4.49 | 5.22 | 5.60 | 5.91 | 5.83 | 4.98 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Biomerica, Inc. |
| Country |
United States |
| Employees |
54 |
| CEO |
Zackary S. Irani |
Stock Information
| Ticker Symbol |
BMRA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Diagnostics & Research |
| Unique Identifier |
NASDAQ: BMRA |
Description
Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It primarily offers its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the point of care and clinical laboratories worldwide. The company is also developing InFoods, an irritable bowel syndrome (IBS) therapy technology and diagnostic-guided therapy, which is in clinical studies to identify specific foods that when removed from the patient's diet can alleviate the patient's IBS symptoms. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.